Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748862 | 0.79 | GAA (0.44) | PTGS2KIF11 | |
| SCHEMBL8901059 | 0.78 | LMNA (0.43) | — | |
| SCHEMBL1866562 | 0.76 | ENPP2 (0.43) | ENPP2PTGS2 | |
| SCHEMBL3066974 | 0.76 | ENPP2 (0.43) | ENPP2PTGS2 | |
| SCHEMBL11648395 | 0.74 | ENPP2 (0.41) | ENPP2PTGS2KIF11 | |
| SCHEMBL3591711 | 0.74 | ENPP2 (0.52) | ENPP2PTGS2 | |
| SCHEMBL1045428 | 0.74 | ENPP2 (0.41) | ENPP2PTGS2PTGS1 | |
| SCHEMBL8796791 | 0.74 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL1097336 | 0.71 | SMN1; SMN2 (0.43) | ENPP2PTGS2PTGS1 | |
| SCHEMBL23411215 | 0.70 | ENPP2 (0.34) | ENPP2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | claimed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | claimed |
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| WO-1989001932-A1 | 2-ALKYL AND 2-ALKENYL SUBSTITUTED 1,4-DIHYDROPYRIDINES, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-03-09 | — | — | WO | claimed |
| EP-0305983-A1 | 2-Alkyl and 2-alkenyl substituted 1,4-dihydropyridines, a method for their preparation and pharmaceutical compositions containing them | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1989-03-08 | — | — | EP | claimed |
| EP-4304585-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230303608-A1 | DITHIOLENE METAL COMPLEXES | BASF SCHWEIZ AG (CH) | 2023-09-28 | — | — | US | disclosed |
| EP-4182395-A1 | DITHIOLENE METAL COMPLEXES | BASF SE (DE) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-1658857-A | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658856-A | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| CN-1658858-A | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| WO-1989001932-A1 | 2-ALKYL AND 2-ALKENYL SUBSTITUTED 1,4-DIHYDROPYRIDINES, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-03-09 | — | — | WO | disclosed |
| EP-0305983-A1 | 2-Alkyl and 2-alkenyl substituted 1,4-dihydropyridines, a method for their preparation and pharmaceutical compositions containing them | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303608-A1 | DITHIOLENE METAL COMPLEXES | TST, C1S, F12 | ENPP2 3182/4885PTGS2 2479/4885PTGS1 2663/4885 |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | ENPP2 728/4885PTGS2 2617/4885PTGS1 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.